Celadon Pharmaceuticals PLC Publication of Annual Report and Notice of AGM (6904B)
June 05 2023 - 8:46AM
UK Regulatory
TIDMCEL
RNS Number : 6904B
Celadon Pharmaceuticals PLC
05 June 2023
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Publication of Annual Report and Notice of Annual General
Meeting
London, 5 June 2023 - Celadon Pharmaceuticals Plc, a leading UK
based pharmaceutical company focused on the development and supply
of natural cannabis-based medicines, announces that copies of the
2022 Annual Report and Accounts, together with its Notice of 2023
Annual General Meeting ("AGM"), were posted to shareholders today
and are available for viewing on the Company's website
www.celadonpharma.com .
The Company will be holding its AGM at 12 noon on Thursday 29
June 2023 at the offices of CMS Cameron McKenna Nabarro Olswang
LLP, Cannon Place, 78 Cannon Street, London EC4N 6AF.
Enquiries:
Celadon Pharmaceuticals Plc
James Short Via Powerscourt
Jonathan Turner
Canaccord Genuity Limited (Nominated
Adviser and Broker)
Bobbie Hilliam/Andrew Potts / Patrick
Dolaghan +44 (0)20 7523 8000
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums
/
Ibrahim Khalil +44 (0)20 7250 1446
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company
focused on the research, cultivation, manufacturing, and sale of
breakthrough cannabis-based medicines. Its primary focus is on
improving quality of life for chronic pain sufferers, as well as
exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP
approved and comprises indoor hydroponic cultivation, proprietary
GMP extraction and manufacturing and an analytical and R&D
laboratory. Celadon's Home Office licence allows for the commercial
supply of its GMP pharmaceutical cannabis product. The Company's
subsidiary, LVL, owns a MHRA conditionally-approved clinical trial
using cannabis based medicinal products to treat chronic pain in
the UK . Celadon also has a minority interest in early-stage
biopharma Kingdom Therapeutics which is developing a licenced
cannabinoid medicine to treat children with Autism Spectrum
Disorder.
For further information please visit our website www.celadonpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAXELFBXQLZBBZ
(END) Dow Jones Newswires
June 05, 2023 09:46 ET (13:46 GMT)
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From May 2024 to Jun 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2023 to Jun 2024